Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The β-haemoglobinopathies are the most prevalent inherited disorders worldwide. Gene therapy of β-thalassaemia is particularly challenging given the requirement for massive haemoglobin production in a lineage-specific manner and the lack of selective advantage for corrected haematopoietic stem cells. Compound βE/β0-thalassaemia is the most common form of severe thalassaemia in southeast Asian countries and their diasporas. The βE-globin allele bears a point mutation that causes alternative splicing. The abnormally spliced form is non-coding, whereas the correctly spliced messenger RNA expresses a mutated βE-globin with partial instability. When this is compounded with a non-functional β0 allele, a profound decrease in β-globin synthesis results, and approximately half of βE/β0-thalassaemia patients are transfusion-dependent. The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months. Blood haemoglobin is maintained between 9 and 10 g dl−1, of which one-third contains vector-encoded β-globin. Most of the therapeutic benefit results from a dominant, myeloid-bia…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, this response was associated with a relative increase in a dominant myeloid clone bearing a lentiviral vector insertion within the HMGA2 gene locus.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“In the initial study of HSCs transduced with β-globin in patients with β-thalassemia, one patient with βE/β0-thalassemia achieved independence from transfusion [67].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [67]
In the citing paper
“The relative clonal dominance at the HMGA2 locus that was initially observed in 1 patient in the LG001 study of the HPV569 vector spontaneously subsided while that patient maintained stable HbA T87Q levels.”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
In the citing paper
“The feasibility of the addition of a gene to autologous hematopoietic cells using a lentiviral vector was shown previously in a single patient with β-thalassemia who safely discontinued transfusions for more than 6 years with ongoing, sustained β A-T87Q -globin expression.14,20”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
MicroRNA maturation: stepwise processing and subcellular localization
Lee, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf476 · Cited by 2,478
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“To demonstrate that only one integrated vector provirus was present in cells with the HMGA2 IS, three qPCR experiments were simultaneously performed on the same genomic DNA preparation with primers specific for either (1) a ‘HIV gag packaging signal’ DNA sequence (common to all vector provirus regardless of IS); (2) t…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chung, J. H., Whiteley, M., & Felsenfeld, G. (1993) · Cell · doi:10.1016/0092-8674(93)80052-g · Cited by 854
Lin28 promotes transformation and is associated with advanced human malignancies
Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., O'Sullivan, M., Lu, J., Phillips, L. A., Lockhart, V. L., et al. (2009) · Nature Genetics · doi:10.1038/ng.392 · Cited by 814
Long-Term Propagation of Distinct Hematopoietic Differentiation Programs In Vivo
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee, S.-J., Brinkman, R., & Eaves, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.015 · Cited by 609
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Self-citationMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567 · cited 1×
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
Background
Cited by
Items 701–800 of 1,000
Aberrant splicing events caused by insertion of genes of interest into expression vectors
Cheng, Y., Kang, X.-Z., Chan, P., Ye, Z., Chan, C., & Jin, D. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72408 · Cited by 16
“Particularly, in a clinical trial for gene therapy of β-thalassemia, an aberrantly spliced mRNA encoding a truncated HMGA2 protein has acquired clonal dominance and exhibited a beneficial effect [38].”
BackgroundGene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 18
Wan, J., Tian, P.-L., Luo, W., Wu, B., Xiong, F., Zhou, W., Wei, X., & Xu, X. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.05.041 · Cited by 15
An Evolving Model of Hematopoietic Stem Cell Functional Identity
Lensch, M. W. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-012-9347-x · Cited by 18
“However, in a beta-thalassemia trial, a restricted erythroid/granulocytic myeloid clone developed over time containing a unique integration site within the HMGA2 gene; a site which was not seen in lymphoid cells [56].”
Modeling Normal and Disordered Human Hematopoiesis
Beer, P. A., & Eaves, C. J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.09.002 · Cited by 15
“In fact, transplantation of patients with lentivirus-modified autologous cells is now providing increasingly detailed studies of the long-term effects of specific corrective genetic strategies on the in vivo behavior of human hematopoietic cells, as well as tracking their innate output activities in an autologous cont…”
BackgroundBarker, J. C., Barker, A. D., Bills, J. D., Huang, J., Wight‐Carter, M., Delgado, I., Noble, D. L., Huang, L. J.-S., Porteus, M. H., & Davis, K. E. (2014) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000000427 · Cited by 17
Zhou, S., Bonner, M. A., Wang, Y., Rapp, S., Ravin, S. S. D., Malech, H. L., & Sorrentino, B. P. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.122 · Cited by 15
“8 The dominant clone has been reported to be stable in size and may reflect oligoclonal repopulation arising from transplant of limited numbers of transduced hematopoietic stem cells (HSCs) rather than growth perturbation per se .”
Alonso, L., González‐Vicent, M., Beléndez, C., Badell, I., Sastre, A., Rodríguez-Villa, A., Cortés, M. B., Hladun, R., & de Heredia, C. D. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.05.013 · Cited by 15
Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization
Hu, P., Bi, Y., Ma, H., Suwanmanee, T., Zeithaml, B., Fry, N. J., Kohn, D. B., & Kafri, T. (2018) · Gene Therapy · doi:10.1038/s41434-018-0039-2 · Cited by 18
Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9
Byambaa, S., Uosaki, H., Ohmori, T., Hara, H., Endo, H., Nureki, O., & Hanazono, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.001 · Cited by 15
Platelet‐delivered therapeutics
Lyde, R. B., Sabatino, D. E., Sullivan, S. K., & Poncz, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12938 · Cited by 16
Hu, P., Li, Y., Sands, M. S., McCown, T. J., & Kafri, T. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.25 · Cited by 15
Capone, F., Nappi, F., & Galli, M. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00011-x · Cited by 18
Uchida, N., Weitzel, R. P., Evans, M., Green, R., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Hsieh, M. M., Donahue, R. E., & Tisdale, J. F. (2013) · Gene Therapy · doi:10.1038/gt.2013.67 · Cited by 15
GWAS to Therapy by Genome Edits?
Hardison, R. C., & Blobel, G. A. (2013) · Science · doi:10.1126/science.1245813 · Cited by 15
O’Reilly, M., Kohn, D. B., Bartlett, J. S., Benson, J. M., Brooks, P. J., Byrne, B. J., Camozzi, C. R., Cornetta, K. G., Crystal, R. G., Fong, Y., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.064 · Cited by 15
“Some clinical improvements have been observed in trials for X-adrenoleukodystrophy (Cartier et al., 2009) and b thalassemia (Cavazzana-Calvo et al., 2010) using lentiviral vectors, and trials are being planned for several other diseases.”
BackgroundSelf-citationGene therapy's out-of-body experience
Scott, C. T., & DeFrancesco, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3592 · Cited by 17
Integration Site Analysis in Gene Therapy Patients: Expectations and Reality
Biasco, L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.183 · Cited by 17
“28,29”
Taştan, C., Kançağı, D. D., Turan, R. D., Yurtsever, B., Çakırsoy, D., Abanuz, S., Yılancı, M., Seyis, U., Özer, S., Mert, S., et al. (2020) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2020.2020.0070 · Cited by 16
“However, TFF can also perform diafiltration to remove metabolites and small secreted proteins from HEK293T cell supernatant as well as the residual Benzonase, which was used as a nuclease treatment to degrade plasmids and other nucleic acid contaminants [30,31,40].”
BackgroundRecent Approaches for Manipulating Globin Gene Expression in Treating Hemoglobinopathies
Mussolino, C., & Strouboulis, J. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618111 · Cited by 18
“Randomly integrating viral vectors expressing β-globin are currently exploited in multiple trials to correct the phenotype of β-thalassemic and SCD patients (Cavazzana-Calvo et al., 2010; Ikawa et al., 2019).”
BackgroundLentiviral interferon: A novel method for gene therapy in bladder cancer
Mokkapati, S., Narayan, V. M., Manyam, G. C., Lim, A. H., Duplisea, J. J., Kokorovic, A., Miest, T. S., Mitra, A. P., Plote, D., Anand, S. S., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.06.005 · Cited by 16
Gene and Cellular Therapies for Leukodystrophies
Aerts‐Kaya, F., & van Til, N. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112522 · Cited by 15
“…third generation, self-inactivating lentiviral vectors that have been used in multiple clinical trials for X-ALD [36], MLD [66,68], β -thalassemia [85] and Wisko tt -Aldrich syndrome [86] have been shown to be considerably safer. clinical trials for X-ALD [36], MLD [66,68], β -thalassemia [85]…”
BackgroundPapanikolaou, E., Paruzynski, A., Kasampalidis, I. N., Deichmann, A., Stamateris, E., Schmidt, M., Kalle, C. V., & Anagnou, N. P. (2014) · Molecular Therapy · doi:10.1038/mt.2014.246 · Cited by 14
Lack of genotoxicity due to foamy virus vector integration in human iPSCs
Deyle, D. R., Khan, I., Ren, G., & Russell, D. W. (2013) · Gene Therapy · doi:10.1038/gt.2013.6 · Cited by 16
Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting
Cesani, M., Plati, T., Lorioli, L., Benedicenti, F., Redaelli, D., Dionisio, F., Biasco, L., Montini, E., Naldini, L., & Biffi, A. (2015) · Gene Therapy · doi:10.1038/gt.2015.10 · Cited by 15
Human Involucrin Promoter Mediates Repression-Resistant and Compartment-Specific LEKTI Expression
Di, W., Semenova, E., Larcher, F., Río, M. D., Harper, J. I., Thrasher, A. J., & Qasim, W. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.091 · Cited by 14
“…region HS4 element (cHS4) into retroviral LTR regions to reduce expression variegation, but their inclusion may compromise vector titer (Gaszner and Felsenfeld, 2006), and a recent clinical report has raised questions about their inclusion in therapeutic vectors (Cavazzana-Calvo et al. , 2010).”
Kinetics of lentiviral vector transduction in human CD34+ cells
Uchida, N., Green, R. M., Ballantine, J., Skala, L. P., Hsieh, M. M., & Tisdale, J. F. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.10.003 · Cited by 14
Haemoglobin disorders in Australia: where are we now and where will we be in the future?
Crighton, G. L., Wood, E. M., Scarborough, R., Ho, P. J., & Bowden, D. K. (2016) · Internal Medicine Journal · doi:10.1111/imj.13084 · Cited by 14
Phanthong, P., Borwornpinyo, S., Kitiyanant, N., Jearawiriyapaisarn, N., Nuntakarn, L., Saetan, J., Nualkaew, T., Sa‐ngiamsuntorn, K., Anurathapan, U., Dinnyés, A., et al. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.16-0121 · Cited by 14
Linden, N., & Jones, R. B. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.06.001 · Cited by 16
Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis
Parrow, N. L., Gardenghi, S., & Rivella, S. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.22 · Cited by 17
Gomez, J., Pichon, C., & Midoux, P. (2013) · Gene · doi:10.1016/j.gene.2013.03.055 · Cited by 14
Drakopoulou, E., Georgomanoli, M., Lederer, C. W., Kleanthous, M., Costa, C., Bernadin, O., Cosset, F., Voskaridou, E., Verhoeyen, E., Papanikolaou, E., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.022 · Cited by 14
Advances in Sickle Cell Disease Treatments
Pavan, A. R., & dos Santos, J. L. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610175400 · Cited by 16
TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product
Straetemans, T., Janssen, A., Jansen, K., Doorn, R., Aarts, T., van Muyden, A. D. D., Simonis, M., Bergboer, J., de Witte, M., Sebestyen, Z., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.030 · Cited by 13
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad
Baena, J. C., Pérez, L. M., Toro-Pedroza, A., Kitawaki, T., & Loukanov, A. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313157 · Cited by 15
Gene therapy for primary immunodeficiencies
Kildebeck, E., Checketts, J., & Porteus, M. H. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328359e480 · Cited by 15
Browning, D. L., Collins, C. P., Hocum, J. D., Leap, D. J., Rae, D. T., & Trobridge, G. D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.110 · Cited by 14
Adelvand, P., Hamid, M., & Sardari, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1406795 · Cited by 14
“Apart from the problems associated with receiving regular blood transfusions, including iron overload, transmission of infectious diseases, and also the risk of developing RBC alloantibodies [5], the other conventional substitution therapy, such as stem cell therapy, is also considered a challenging approach due to th…”
BackgroundIdentification of the minimum requirements for successful haematopoietic stem cell transplantation
Nishi, K., Sakamaki, T., Sadaoka, K., Fujii, M., Takaori‐Kondo, A., Chen, J. Y., & Miyanishi, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17867 · Cited by 13
“On the other hand, ex vivo manipulations of HSCs, such as cell sorting, genetic engineering and cell culture, are likely to lose or abnormalise significantly HSC functions, resulting in the lack of persistent therapeutic effect(11,12) or the increased risk of leukaemogenesis.(13) To solve these issues, starting from p…”
BackgroundZhou, J., Ge, Q., Wang, D., Guo, Q., & Tao, Y. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112385 · Cited by 13
Nieto-Romero, V., García-Torralba, A., Molinos-Vicente, A., Moya, F., Rodríguez, S., García‐Escudero, R., SALIDO, E. C., Segovia, J. C., & García-Bravo, M. (2024) · iScience · doi:10.1016/j.isci.2024.109530 · Cited by 13
Clinical potential of gene therapy: towards meeting the demand
Macpherson, J. L., & Rasko, J. E. J. (2014) · Internal Medicine Journal · doi:10.1111/imj.12366 · Cited by 17
Bone Marrow as a Source of Hematopoietic Stem Cells for Human Gene Therapy of β-Thalassemia
Frittoli, M. C., Biral, E., Cappelli, B., Zambelli, M., Roncarolo, M. G., Ferrari, G., Ciceri, F., & Marktel, S. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.045 · Cited by 13
“In a patient with B E /B 0 thalassemia (Cavazzana-Calvo et al. , 2010), a dose of 3.9 (cid:2) 10 6 gene-modified BM-derived CD34 þ cells/kg (0.6 vector per cell) was successful in conferring transfusion independency.”
InfluentialVets, S., Rijck, J. D., Brendel, C., Grez, M., Bushman, F. D., Debyser, Z., & Gijsbers, R. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.4 · Cited by 13
Self-citationSjeklocha, L. M., Park, C. W., Wong, P. Y.-P., Roney, M., Belcher, J. D., Kaufman, D. S., Vercellotti, G. M., Hebbel, R. P., & Steer, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029110 · Cited by 15
Uchida, N., Hsieh, M. M., Washington, K. N., & Tisdale, J. F. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.04.014 · Cited by 13
Surface modification via strain-promoted click reaction facilitates targeted lentiviral transduction
Chu, Y., Oum, Y. H., & Carrico, I. S. (2015) · Virology · doi:10.1016/j.virol.2015.09.009 · Cited by 13
Evidence for the in vivo safety of insulated foamy viral vectors
Browning, D. L., Everson, E. M., Leap, D. J., Hocum, J. D., Wang, H., Stamatoyannopoulos, G., & Trobridge, G. D. (2016) · Gene Therapy · doi:10.1038/gt.2016.88 · Cited by 13
Verhovsek, M. M., & Chui, D. H. K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108586900.009 · Cited by 15
Sertkaya, H., Ficarelli, M., Sweeney, N. P., Parker, H., Vink, C. A., & Swanson, C. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-91309-w · Cited by 13
Deakin, C. T., Alexander, I. E., Hooker, C. A., & Kerridge, I. (2013) · Molecular Therapy · doi:10.1038/mt.2012.230 · Cited by 13
Verhoeyen, E., Relouzat, F., Cambot, M., Costa, C., Négre, D., Legrand, F., Joubert, C., Grand, R. L., Cosset, F., Leboulch, P., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.020 · Cited by 13
“…has resulted in proof-of-principle of efficacy in clinical trials for several inherited diseases that include X-linked severe combined immunodeficiency (X-SCID) syndrome (Cavazzana-Calvo et al., 2000), adrenoleukodystrophy (Car- tier et al., 2009), and b-thalassemia (Cavazzana-Calvo et al., 2010).”
BackgroundSelf-citationUchida, N., Weitzel, R. P., Shvygin, A., Skala, L. P., Raines, L. N., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.59 · Cited by 13
Gene Therapy: A Possible Alternative to CFTR Modulators?
Mercier, J., Ruffin, M., Corvol, H., & Guillot, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648203 · Cited by 13
“…deficiency (Cicalese et al., 2016), Leber congenital amaurosis (Cideciyan et al., 2013), hemophilia (Nathwani et al., 2011), severe betaThalassemia (Cavazzana-Calvo et al., 2010; Persons, 2010), but also Parkinson’s disease (Palfi et al., 2014) or leukemia, with 27 children who experienced…”
BackgroundGene Replacement Therapies for Genodermatoses: A Status Quo
Koller, U., & Bauer, J. W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.658295 · Cited by 13
“…of the transgene flanked by viral sequences, or the post-transcriptional deregulation of target endogenous genes by aberrant splicing (Montini et al., 2009; Cavazzana-Calvo et al., 2010; Titeux et al., Frontiers in Genetics | www.frontiersin.org 3 April 2021 | Volume 12 | Article 658295 2010).”
BackgroundNon-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon System™Preprint
Pomeroy, E. J., Lahr, W. S., Chang, J., Krueger, J. B., Wick, B. J., Slipek, N. J., Skeate, J. G., Webber, B. R., & Moriarity, B. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.02.454772 · Cited by 17
Kubota, S., Sun, Y., Morii, M., Bai, J., Ideue, T., Hirayama, M., Sorin, S., Eerdunduleng, E., Yokomizo‐Nakano, T., Osato, M., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00122-4 · Cited by 14
“The overexpression of Hmga2 in WT adult HSCs is not suf fi cient for the development of malignancy in mice and non-human primates (Kumar et al, 2019; Bonner et al, 2021; Sun et al, 2022) and also presumably in humans after gene therapies (Cavazzana-Calvo et al, 2010).”
BackgroundBouziana, S. D., & Bouzianas, D. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179518 · Cited by 15
“…has also been reported in an adult patient with severe β -thalassaemia treated with LV β -globin gene transfer, in whom the integrated vector caused enhancer-mediated transcriptional activation of the HMGA2 gene with increased expression of a truncated HMGA2 mRNA insensitive to degradation [66].”
BackgroundAre monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?
Bhatia, D., Dolcetti, R., & Mazzieri, R. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03359-x · Cited by 13
Integrome signatures of lentiviral gene therapy for SCID-X1 patients
Yan, K., Condori, J., Ma, Z., Métais, J., Ju, B., Ding, L., Dhungana, Y., Palmer, L. E., Langfitt, D. M., Ferrara, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg9959 · Cited by 12
“In all patients except for patient 1, VISs were strongly enriched in actively transcribed regions and enhancers (states 3, 4, 5, and 6) and depleted in repressive regions and heterochromatins (states 9, 13, 14, and 15).”
Tai, D. S., Hu, C., Lee, C. C. I., Martinez, M. L., Cantero, G., Kim, E. H., Tarantal, A. F., & Lipshutz, G. S. (2015) · Gene Therapy · doi:10.1038/gt.2015.65 · Cited by 12
Retrovirus-based vectors for transient and permanent cell modification
Schott, J. W., Hoffmann, D., & Schambach, A. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.004 · Cited by 13
Manic, G., Maurin-Marlin, A., Galluzzi, L., Subra, F., Mouscadet, J. F., & Bury‐Moné, S. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.154 · Cited by 12
“The presence of cHS4 within retroviral vectors appears to reduce the risk of insertional oncogenesis (Evans-Galea et al. , 2007; Ryu et al. , 2007), although one case of clonal dominance has been reported during a clinical trial based on a cHS4-containing SIN vector (Cavazzana-Calvo et al. , 2010).”
Therapeutic effects of induced pluripotent stem cells in chimeric mice with -thalassemia
Yang, G., Shi, W., Hu, X., Zhang, J., Gong, Z., Guo, X., Ren, Z., & Zeng, F. (2014) · Haematologica · doi:10.3324/haematol.2013.087916 · Cited by 12
“reported one effective case in their Phase I/II clinical trial study.(36) However, several recently published reports showed that these approaches remain inefficient.”
BackgroundHMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts
de Vasconcellos, J. F., Lee, Y. T., Byrnes, C., Tumburu, L., Rabel, A., & Miller, J. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166928 · Cited by 13
Park, B.-K., Kim, H., Kim, S., Lee, J. W., Park, Y. S., Jang, P., Chung, N., Jeong, D.-C., & Cho, B. (2018) · Blood Research · doi:10.5045/br.2018.53.2.145 · Cited by 14
Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules
Situ, K., Chua, B. A., Bae, S. Y., Meyer, A. S., & Morizono, K. (2018) · Virology · doi:10.1016/j.virol.2018.09.017 · Cited by 12
“Although integration of vectors into chromosomes enables long-term transgene expression, it can also cause insertional mutagenesis, which can affect expression of specific host genes (Fraietta et al., 2018) (Ranzani et al., 2013) (Cavazzana-Calvo et al., 2010).”
BackgroundIn Vivo Gene Therapy for Canine SCID-X1 Using Cocal-Pseudotyped Lentiviral Vector
Rajawat, Y. S., Humbert, O., Cook, S. M., Radtke, S., Pande, D., Enstrom, M., Wohlfahrt, M. E., & Kiem, H. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.127 · Cited by 14
A complicated disease: what can be done to manage thalassemia major more effectively?
Origa, R., Baldan, A., Marsella, M., & Borgna‐Pignatti, C. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1101339 · Cited by 15
“Although most of the therapeutic benefits resulted from a dominant, myeloid-biased cell clone, in which the integrated vector causes transcriptional activation of HMGA2 (a potential oncogene in various types of cancer) in erythroid cells, this integration seems hitherto benign.[67] After a peak at 22% of nucleated cel…”
BackgroundInnovation and opportunity for chimeric antigen receptor targeted T cells
Melenhorst, J. J., & Levine, B. L. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.007 · Cited by 12
“Lentiviral vectors have not yet been associated with insertional oncogenesis in stem cells, although integration-mediated clonal dominance has been reported in one trial (51).”
BackgroundMartin, S. E., Sausen, M., Joseph, A., Kingham, B. F., & Martin, E. S. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.03.006 · Cited by 13
Yang, S., Karne, N. K., Goff, S. L., Black, M. A., Xu, H., Bischof, D., Cornetta, K. G., Rosenberg, S. A., Morgan, R. A., & Feldman, S. A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.199 · Cited by 13
“However, it should be stated that LVVs, in and of themselves, may not completely solve the problem of insertional mutagenesis, as there has been a single report associating an LVV with clonal dominance in a b -thalassemia trial (Cavazzana-Calvo et al. , 2010).”
Self-citationSalek, S., Ionova, T., Johns, J. R., & Olíva, E. N. (2018) · Quality of Life Research · doi:10.1007/s11136-018-2025-y · Cited by 12
“In addition, gene therapy offers promise as a safe and efficient treatment modality [11–14], similar to that of genetic correction for other diseases such as β-thalassemia in humans [15].”
BackgroundWorgall, S., & Crystal, R. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00034-3 · Cited by 12
Recent Developments in Phosphonium Chemistry
Berchel, M., & Jaffrès, P. (2019) · Organophosphorus chemistry · doi:10.1002/9783527672240.ch2 · Cited by 12
Genetic strategies for the treatment of sickle cell anaemia
Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08773.x · Cited by 12
Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia
Eridani, S., & Mosca (2011) · Journal of Blood Medicine · doi:10.2147/jbm.s14942 · Cited by 13
Gene Therapy for SCID-X1: Focus on Clinical Data
Baum, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.252 · Cited by 13
The European Hospital Exemption Clause—New Option for Gene Therapy?
Buchholz, C. J., Sanzenbacher, R., & Schüle, S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.2529 · Cited by 14
“…(Thrasher et al. , 2006; Gaspar et al. , 2010) or adenosine deaminase-deficient severe combined immunodeficiency (Gaspar et al. , 2006, 2011), b -thalassemia (Cavazzana-Calvo et al. , 2010), Wiskott-Aldrich syndrome (Boztug et al. , 2010), and adrenoleukodystrophy (Cartier et al. , 2009, 2010).”
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Puig-Serra, P., Hinckley-Boned, A., Tristán‐Manzano, M., Río, P., Torres-Ruiz, R., Rodríguez, S., & Martín, F. (2025) · Human Gene Therapy · doi:10.1177/10430342251372474 · Cited by 11
Fischer, A. (2014) · Nature · doi:10.1038/nature13344 · Cited by 11
Self-citationHetzel, M., López-Rodríguez, E., Mucci, A., Nguyen, A. H. H., Suzuki, T., Shima, K., Buchegger, T., Dettmer, S., Rodt, T., Bankstahl, J. P., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.214866 · Cited by 11
“In our study, we employed a 3 generation, safetyimproved SIN vector design, which is also used in current HSC-GT-based approaches targeting other monogenic diseases affecting the lymphohematopoietic system, such as X-linked- or adenosine deaminase-deficient severe combined immunodeficiency (X-SCID, ADA-SCID),(26,27) W…”
MethodHMGA Proteins in Hematological Malignancies
Minervini, A., Coccaro, N., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · Cancers · doi:10.3390/cancers12061456 · Cited by 12
“The improvement on the HSC properties due to the expression of HMGA2 has also been observed in some human gene therapy studies using lenti‐viral or retro‐viral for the transduction of human transgenes [94,95].”
BackgroundCRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 12
“TOWARDS A CURATIVE CRISPR/ CAS9-BASED GENE EDITING APPROACH FOR DOCK8-RELATED PRIMARY IMMUNODEFICIENCY Retroviral gene therapy in autologous HSCs has provided clinical benefit in several PIDs including SCID-X1 (Aiuti et al., 2002; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2010; Gaspar et al., 2011), Adenosine deam…”
BackgroundIntraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice
Joo, J. H., Wang, X., Singh, S., Chen, C., Li, C., Adair, J. E., Kiem, H., Rawlings, D. J., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008079 · Cited by 11
Steinbeck, B. J., Gao, X. D., McElroy, A. N., Pandey, S., Doman, J. L., Riddle, M. J., Xia, L., Chen, W., Eide, C. R., Lengert, A. V. H., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.04.013 · Cited by 12
Dodd, M., Marquez‐Curtis, L. A., Janowska‐Wieczorek, A., & Hortelano, G. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2769 · Cited by 11
“As a result of integration into the host genome, safety is a primary concern when using lentiviral vectors [71].”
BackgroundCuring HIV: lessons from cancer therapy
Mitsuyasu, R. T. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32835ef0a1 · Cited by 13
Gene therapies in clinical trials
Papadopoulos, K. I., Wattanaarsakit, P., Prasongchean, W., & Narain, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100520-0.00010-2 · Cited by 13
Tani, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2030-2 · Cited by 12
“Sickle cell disease (SCD) 1 3 and β-thalassemia major (β-TM), the latter defined clinically as transfusion-dependent cases regardless of the underlying genotype, are the most common monogenic disorders worldwide, with approximately 400,000-affected conceptions or births each year.”
BackgroundInfluentialNucleic Acid Therapy for β-Thalassemia
d’Arqom, A. (2020) · Biologics · doi:10.2147/btt.s265767 · Cited by 16
Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia
Hongeng, S., Anurathapan, U., Songdej, D., Phuphuakrat, A., Jongrak, K., Parsons, G., Deary, B., Bonner, M. A., Veres, G., & Asmal, M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003680 · Cited by 11
“BB305 LVV is a third-generation, replication-defective, self-inactivating (SIN) human immunodeficiency virus-1 (HIV-1)–based LVV that encodes a modified human b-globin gene containing a threonine (T) to glutamine (Q) amino acid substitution at position 87 and regulatory elements of the human b-globin mini-gene that dr…”
BackgroundInsights of CRISPR-Cas systems in stem cells: progress in regenerative medicine
Shanmugam, D. K., Aashabharathi, M., Devi, G. K., Subbaiya, R., & Saravanan, M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06832-w · Cited by 13
Gene therapy and gene editing in healthcare
Dwivedi, S., Purohit, P., Vasudeva, A., Kumar, M., Agrawal, R., Sheikh, N. A., Misra, R., Kishore, S., & Misra, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89837-9.00006-1 · Cited by 18
A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors
Tareen, S. U., Nicolai, C. J., Campbell, D. J., Flynn, P. A., Slough, M. M., Vin, C. D., Kelley-Clarke, B., Odegard, J. M., & Robbins, S. H. (2013) · BioResearch Open Access · doi:10.1089/biores.2013.0037 · Cited by 8
Wang, H., Shun, M.-C., Li, X., Nunzio, F. D., Hare, S., Cherepanov, P., & Engelman, A. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.2 · Cited by 12
Baldow, C., Thielecke, L., & Glauche, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165129 · Cited by 11
Recent Progress on Genetic Diagnosis and Therapy for β-Thalassemia in China and Around the World
Zhang, J., Yan, J., & Zeng, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.228 · Cited by 11
Metadata
- Authors
- Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R., Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chrétien, L., Bernaudin, F., Girot, R., Dorazio, R., Mulder, G.-J., Polack, A., Bank, A., Soulier, J., Larghero, J., Kabbara, N., Dalle, B., Gourmel, B., Socie, G., Chrétien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K., Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-Bey-Abina, S., & Leboulch, P.
- Affiliations
- Inserm (FR)
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- University of Trieste (IT)
- Hôpital Intercommunal de Créteil (FR)
- Hôpital Tenon (FR)
- Columbia University Irving Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Indiana University Indianapolis (US)
- Corresponding author
- Leboulch, Philippe
- ORCID
- Venue
- Nature
- Published
- 2010-09
- Volume
- 467
- Issue
- 7313
- Pages
- 318-322
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3355472
- OpenAlex
- W2136274459
- Cited by
- 1,276
- References
- 32
- Citations by year
- 2026: 14 · 2025: 45 · 2024: 46 · 2023: 53 · 2022: 64 · 2021: 75 · 2020: 76 · 2019: 84 · 2018: 79 · 2017: 97 · 2016: 94 · 2015: 99 · 2014: 94 · 2013: 116 · 2012: 106
- FWCI
- 63.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL090921, HL090921)
- National Institute of Allergy and Infectious Diseases (AI52845, R01AI082020, R01AI052845, AI082020)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- beta-thalassemia, gene therapy, lentiviral vectors, transfusion independence, HMGA2, leukemia risk, hemoglobinopathies, sickle cell disease, hematopoietic stem cells, alternative splicing, hemoglobin
- MeSH terms
- Adolescent, Blood Cells, Blood Transfusion, Bone Marrow Cells, Child, Preschool, Clone Cells, Genetic Vectors, Homeostasis, Humans, Male, Organ Specificity, RNA, Messenger, Time Factors, Genetic Therapy, Transcriptional Activation, Gene Expression, Lentivirus, beta-Thalassemia, HMGA2 Protein, MicroRNAs, beta-Globins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.